Sarepta Crashes After Second Death On Gene Therapy Drug Sarepta Therapeutics shares suffered their steepest drop in years on Monday morning after a second teenage patient died following treatment with Elevidys, the biotech's one-time gene therapy for Duchenne muscular dystrophy (DMD). "These…
Continue reading...